APCER Life Sciences appoints Dr Sutinder Bindra as Global Head of Medical Affairs

Continues to build its globally integrated capabilities by opening a Hong Kong office

APCER Life Sciences, a global provider of safety, medical, regulatory, and technology services headquartered in Princeton, New Jersey, reports that Sutinder Bindra has joined the company as Global Head of Medical Affairs.

Bindra, who was most recently Head of Medical and Clinical Affairs for Pfizer’s Asia-Pacific Region, will lead a fully integrated team to provide Medical Affairs services globally, including the Asia Pacific region, from APCER’s newly established office in Hong Kong.

Bindra had several years of clinical experience in internal medicine and cardiology before joining the pharmaceutical industry in 1993.

The new APCER Life Sciences Hong Kong office is located in the Bank of East Asia Harbour View Centre in Wan Chai, at the heart of the city’s Central Business District.

You may also like

Regulatory

Broughton receives flexible scope ISO 17025 accreditation

New certification allows accreditation without prior approval
Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Regulatory

Isospec Analytics launches biomolecular analysis technology to identify unknown molecules

The novel technology optimises the identification process of unknown molecules compared to mass analysis
Regulatory

4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA

The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
Subscribe now